Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-02-20 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
股东股份变动结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the results of changes in shareholder holdings, specifically detailing the shareholding changes of a major shareholder and related parties. It includes data on share quantities, percentages, transaction dates, and prices. This type of document corresponds to notifications about changes in significant share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document is not a full financial report, earnings release, or regulatory filing, but a specific disclosure about shareholding changes.
2024-02-20 Chinese
关于控股股东部分股份解除质押及重新办理质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the impact on control and risk. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledging activities that does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing.
2024-02-07 Chinese
2023年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast (业绩预告) for Lingkang Pharmaceutical Group Co., Ltd. It provides preliminary estimated financial results for the full year 2023, including expected net profit and revenue figures. The document explicitly states that the data is unaudited and preliminary, and that the final accurate financial data will be disclosed in the formal 2023 annual report. The document length is short (1026 characters), and it serves as an announcement of expected financial results rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is ER with high confidence. FY 2023
2024-01-30 Chinese
关于股份回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the results of its share repurchase program and changes in shareholding. It details the number of shares repurchased, prices, total amounts, and the impact on shareholding structure. It also mentions the use of repurchased shares for employee stock plans or equity incentives. The document is relatively short (2020 characters) and focuses on the share buyback implementation and shareholding changes, not a full financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on company share repurchases or issuances.
2024-01-30 Chinese
关于控股股东进行股票质押式回购交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a stock pledge repurchase transaction by the controlling shareholder of the company. It details the number of shares pledged, the pledge terms, and the impact on the company. There are no financial statements or comprehensive financial data presented. The document is a specific update on financing activities related to share pledges, which fits the category of Capital/Financing Update (CAP). The document length is short and focused on a financing event, not a full report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2024-01-24 Chinese
关于控股股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the proportion of shares involved, and the remaining pledged shares. There is no financial report, earnings data, or management discussion. The document is a regulatory disclosure about share pledge status, which fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories like share issue or director dealings.
2024-01-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.